Safety of Nanoparticles in Medicine
Безопасность наночастиц в медицине
2015-11-19
SCID: 54.1/hnmh3y58
Discuss with AI
nanomedicinenanoparticle safetynanoparticle safety assessmentnanoparticle toxicitysurface modification
Figures from the paper
Abstract (AI)
Nanomedicine involves the use of nanoparticles for therapeutic and diagnostic purposes. During the past two decades, a growing number of nanomedicines have received regulatory approval and many more show promise for future clinical translation. In this context, it is important to evaluate the safety of nanoparticles in order to achieve biocompatibility and desired activity. However, it is unwarranted to make generalized statements regarding the safety of nanoparticles, since the field of nanomedicine comprises a multitude of different manufactured nanoparticles made from various materials. Indeed, several nanotherapeutics that are currently approved, such as Doxil and Abraxane, exhibit fewer side effects than their small molecule counterparts, while other nanoparticles (e.g. metallic and carbon-based particles) tend to display toxicity. However, the hazardous nature of certain nanomedicines could be exploited for the ablation of diseased tissue, if selective targeting can be achieved. This review discusses the mechanisms for molecular, cellular, organ, and immune system toxicity, which can be observed with a subset of nanoparticles. Strategies for improving the safety of nanoparticles by surface modification and pretreatment with immunomodulators are also discussed. Additionally, important considerations for nanoparticle safety assessment are reviewed. In regards to clinical application, stricter regulations for the approval of nanomedicines might not be required. Rather, safety evaluation assays should be adjusted to be more appropriate for engineered nanoparticles.
Key Findings
1
Approved nanotherapeutics such as Doxil and Abraxane can produce fewer side effects than corresponding small-molecule treatments.
2
Metallic and carbon-based nanoparticles commonly display toxicity, although their hazards could support targeted ablation of diseased tissue.
3
Nanoparticle safety cannot be generalized because nanomedicines differ substantially in composition, structure, and biological behavior.
4
Nanoparticle toxicity can affect molecular, cellular, organ, and immune-system functions, requiring assessment across multiple biological levels.
5
Rather than imposing stricter approval regulations, safety assays should be adapted to better evaluate engineered nanoparticles.
6
Surface modification and immunomodulator pretreatment are identified as strategies for improving nanoparticle safety.
Research Object
manufactured nanoparticles used in nanomedicine, including therapeutic and diagnostic nanomedicines
Research Subject
their molecular, cellular, organ, and immune-system toxicity, biocompatibility, and strategies and assessment considerations for improving and evaluating safety
Publication Details
Publication Date
2015-11-19
Journal
Publisher
ISSN
Cited by
534
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest